Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
- Beneficial Effects of Fenofibrate to Improve Endothelial Dysfunction and Raise Adiponectin Levels in Patients With Primary Hypertriglyceridemia. Koh, Kwang Kon; Han, Seung Hwan; Quon, Michael J.; Ahn, Jeong Yeal; Shin, Eak Kyun // Diabetes Care;Jun2005, Vol. 28 Issue 6, p1419
OBJECTIVE -- Improvement in endothelial function is predicted to improve insulin sensitivity, and this may be one mechanism by which fenofibrate decreases the incidence of coronary, heart disease. We hypothesize fenofibrate improves endothelial function by enhancing insulin sensitivity. RESEARCH...
- Effect of Type 1 Diabetes on the Gender Difference in Coronary Artery Calcification: a Role for Insulin Resistance? Dabelea, Dana; Kinney, Gregory; Snell-Bergeon, Janet K.; Hokanson, John E.; Hamman, Richard F.; Eckel, Robert H.; Ehrlich, James; Garg, Satish; Rewers, Marian // Diabetes;Nov2003, Vol. 52 Issue 11, p2833
The objective of this is study was to examine whether estimated insulin resistance and insulin resistancerelated factors are associated with coronary artery calcification (CAC) in 1,420 asymptomatic participants in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. A total of...
- Combination fecal testing is most effective strategy for finding cancers. // Modern Medicine;Jun96, Vol. 64 Issue 6, p51
Presents the abstract of the study entitled `A Comparison of Fecal Occult-Blood Tests for Colorectal-Cancer Screening,' by Allison, Tekawa et al published in the January 18, 1996 issue of the `New England Journal of Medicine' periodical concerning the diagnosis of colonic cancers.
- Screen for colorectal cancer once a year. Begany, Timothy // RN;Dec93, Vol. 56 Issue 12, p17
Reports on the lower mortality rate of men and women tested annually for colorectal cancer by fecal occult-blood testing. `New England Journal of Medicine' as source; Mortality for those screened every two years; Discovery and treatment at an earlier age.
- What to do now to screen for colorectal cancer. Glaser, Vicki; Early, Dayna S.; Fletcher, Robert; Rodney, W.M. MacMillan // Patient Care;6/15/1998, Vol. 32 Issue 11, p206
Focuses on issues pertaining to screening for colorectal cancer. Characteristics of colorectal cancer which make it an excellent target for systematic screening; Information on the American Cancer Society (ACS) guidelines regarding screening for colorectal cancer; When should screening for...
- Gene Screen for Early Colon Cancer. J.M. // Prevention;Jul2002, Vol. 54 Issue 7, p159
Reports on a test called Digital Protein Truncation to detect early-colon cancer.
- New diagnostic criteria for HNPCC are on the way. Kuska, Bob // JNCI: Journal of the National Cancer Institute;01/01/97, Vol. 89 Issue 1, p11
Reports on a diagnostic Bethesda criteria for hereditary non-polyposis colon cancer (HNPCC). Similarity with a sporadic colon tumor; Genetically oriented criteria for the diagnosis of HNPCC; Testing for mutations in the HNPCC genes.
- Experts call for action to prevent colon cancer deaths by spurring screening awareness. Steimle, Sabine // JNCI: Journal of the National Cancer Institute;03/19/97, Vol. 89 Issue 6, p415
Reports on the development of guidelines for colorectal cancer screening in the United States. Availability of screening options; Criticisms on the guidelines; Benefits of the annual or bi-annual fetal occult blood test. INSET: Colorectal cancer incidence..
- Randomized, double-blinded, placebo-controlled study of... Alberts, David S.; Ritenbaugh, Cheryl // JNCI: Journal of the National Cancer Institute;1/17/96, Vol. 88 Issue 2, p81
Presents the results of a study conducted on the potential mechanisms by which added dietary interventions might reduce colorectal cancer risks. How the study was conducted; Results; Statistical analysis; Conclusion.